Dawn Chen
Profile
Dawn Chen worked as a Biochemistry Director at Arête Therapeutics, Inc. from 2006 to 2011.
Prior to that, she worked as a Principal at Vicuron Pharmaceuticals LLC and Affymax, Inc. Dr. Chen holds a graduate degree from the University of Alberta and a doctorate degree from Shanghai Jiao Tong University.
Former positions of Dawn Chen
Companies | Position | End |
---|---|---|
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Corporate Officer/Principal | - |
AFFYMAX, INC. | Corporate Officer/Principal | - |
Arête Therapeutics, Inc.
Arête Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Arête Therapeutics, Inc. develops and commercializes molecule drugs to treat cardiovascular and inflammatory diseases. It focuses on developing AR9281, an orally-administered compound that inhibits s-EH (soluble epoxide hydrolase), an enzyme that plays a key role in the metabolism of arachidonic acid. It also focuses on testing various back-up candidates as additional first-in-class anti-hypertensive plus agents. The company was founded in 2003 and is headquartered in Hayward, CA. | Corporate Officer/Principal | - |
Training of Dawn Chen
Shanghai Jiao Tong University | Doctorate Degree |
University of Alberta | Graduate Degree |
Experiences
Positions held
Linked companies
Listed companies | 1 |
---|---|
AFFYMAX, INC. | Health Technology |
Private companies | 2 |
---|---|
Arête Therapeutics, Inc.
Arête Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Arête Therapeutics, Inc. develops and commercializes molecule drugs to treat cardiovascular and inflammatory diseases. It focuses on developing AR9281, an orally-administered compound that inhibits s-EH (soluble epoxide hydrolase), an enzyme that plays a key role in the metabolism of arachidonic acid. It also focuses on testing various back-up candidates as additional first-in-class anti-hypertensive plus agents. The company was founded in 2003 and is headquartered in Hayward, CA. | Health Technology |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
- Stock Market
- Insiders
- Dawn Chen